R heumatoid arthritis (RA) is a disorder comprising a complex onset mechanism and many associated complications. In particular, cardiovascular disease (CVD) significantly contributes to morbidity and mortality in these patients, causing the 39% to 50% of deaths, 1 and atherosclerosis at early stage of the disease is considered a possible preclinical manifestation. In fact, the risk of CVD events, such as myocardial infarction, is increased in the 2 years preceding formal diagnosis of RA, 2 and once the disease is diagnosed, the risks of carotid plaques and CVD events increase with the duration of RA. 3 Thus, the strong relationship between atherosclerosis and RA has led some authors to include atherosclerosis among the extra-articular manifestations of the disease. 4 The mechanisms responsible for the premature atherosclerosis in RA are not well understood, but traditional risk factors alone are not fully responsible and a role of inflammation in this process has been suggested. Considering that RA is a chronic inflammatory disease and the pathogenic role of inflammation in the atherosclerosis, 5 it is likely that inflammatory mediators might be causal in the accelerated atherosclerosis observed in RA.
Oxidative stress is another process frequently altered in RA, which also contributes to atherosclerosis, being associated with a poorer prognosis. Neutrophils are thought to be responsible for the elevated levels of reactive oxygen species found in plasma and synovial fluid of RA patients, thus contributing to the joint tissue damage within synovial membrane. 6 In addition, a positive correlation has recently been shown between neutrophils reactive oxygen species levels in blood and synovial fluid with disease activity score (DAS)-28, C reactive protein (CRP), and anticyclic citrullinated protein (CCP) levels. 7 However, monocytes also seem to contribute to the elevated oxidative stress in blood of RA patients through the production of superoxide anion. 8 Many different cell components can be considered as key elements in the long course of RA, including blood white cells, such as lymphocytes, monocytes, and neutrophils. Activation of these cells leads to the production of cytokines and mediators of inflammation, oxidative stress, and atherosclerosis. In this regard, monocytes/macrophages are central players in inflammation and have been found to be activated in RA through the release of cytokines 9 and massive infiltration in inflammatory sites, such as synovial membranes. 10 In addition, monocytes/macrophages have been associated with bone erosion in RA, owing to their excessive differentiation into osteoclasts. 11 Because of its role in RA, several monocyte-targeted therapies are being developed.
Lymphocytes are the most studied cells mediating the pathogenesis of RA, which in fact is considered a T helper 1 (Th1) cell-driven disorder with a Th1/Th2 imbalance toward higher Th1 levels compared with healthy donors. 12 Th1 releases inflammatory molecules, such as interferon-γ, interleukin (IL)-2, and tumor necrosis factor-α (TNFα), that prevent CD4 + T cells from differentiating into Th2 cells. Moreover, Th17 has lately been associated with RA pathogenesis, 13 mainly producing IL-17A, IL-6, and TNFα, cytokines that are increased in serum of RA patients and are responsible for the activation of other cells. On the other hand, regulatory T cells (Treg) also participate in the course of this disease. They play an important role in immunosuppression through cell-cell interaction and are found significantly decreased at advanced stage, and their function has been shown impaired in RA. 12 Thus, it has been proposed that the development and progression of RA is caused by the imbalance of Th1/Th2 and Th17/Treg cells.
Neutrophils are the most abundant cells in the synovial fluid of affected joints and at the pannus/cartilage interface, where tissue damage occurs. They promote damage through the induction of oxidative stress, enzyme release, and expression of proinflammatory cytokines. However, the role of neutrophils in RA pathogenesis is not fully understood. 14 Among the auto-antibodies detected in RA, the anti-CCPs are highly specific for this disease 15 because IgM rheumatoid factor (RF) is also present in an elevated percentage of patients with several chronic infections. Moreover, atherosclerosis status in RA is independent of RF levels. 16 In contrast, detection of anti-CCP antibodies has become a useful diagnostic tool, particularly at early stage. 17 Thus, the new 2010 RA classification criteria included detection of anti-CCPs as a key item for diagnosing the disease. 18 High levels of anti-CCPs have been suggested to predict an adverse cardiovascular profile in RA patients. However, that hypothesis just arises from association studies in various cohorts, and no study has still demonstrated a direct effect of anti-CCPs in all those processes.
Here we demonstrate the direct involvement of anti-CCPs, purified from RA patients, in the induction of a pro-oxidative, proinflammatory, and atherogenic status in different leukocyte subsets. In addition, specific effects on macrophage activation and survival were also demonstrated.
Materials and Methods
Material and methods are available in the online-only Data Supplement.
Results

Clinical and Analytic Details of RA Patients
Clinical details of RA patients and healthy donors included in this study are stated in Table 1 . A 50.66% of RA patients was positive for RF, whereas 65.33% presented anti-CCP antibodies. The patients included in the present study had a low-moderate disease activity with a DAS28 of 3.49±0.17, considering moderate level of disease DAS28 values from 2.4 to 3.7 and low level DAS28<2.4.
19 CRP was significantly increased in RA patients compared with healthy donors. As an early atherosclerotic marker, pathological CIMT was found in 21.3% of the RA patients.
Altered Expression of Prothrombotic and Inflammatory Markers in Plasma of RA Patients
Compared with healthy donors, RA patients displayed elevated plasma levels of prothrombotic and inflammatory molecules, such as IL-2, IL-6, IL-8, IL-10, IL-17A, IL-23, monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1α (MIP-1α), sP-selectine, TNFα, and tissue plasminogen activator ( Figure 1A ). In both cell populations, a high percentage of cells with mitochondrial membrane depolarization was further observed ( Figure 1B ). In contrast, intracellular reduced glutathione was found in both cell types ( Figure 1C ). In addition, a significant drop in total antioxidant capacity in plasma from RA patients was observed (P=0.002). Nitric oxide levels were lower in plasma from RA patients versus healthy controls (P=0.049), likely because of its consumption after reacting with anion superoxide and the subsequent formation of peroxynitrite, as suggested by the elevated protein tyrosine nitration in plasma (P=0.046; Table I in the online-only Data Supplement).
Correlations and Associations Among
Autoantibodies, Atherosclerosis, and Inflammatory/ Oxidative Stress Markers in RA Patients
In our cohort of patients with RA, anti-CCPs levels positively correlated with age and DAS28 index (P=0.024 and P=0.001, respectively). A further positive correlation was demonstrated among the anti-CCPs levels and inflammatory plasma markers, such as erythrocyte sedimentation rate*, CRP**, IL-2**, IL-8*, IL-6*, IL-17A**, IL-23**, MCP-1**, MIP-1α**, TNFα*, matrix metalloprotease-3*, sP-selectine*, tissue plasminogen activator**, and vascular endothelial growth factor-A** (*P<0.05 and **P<0.01). In relation to oxidative stress, anti-CCP levels positively correlated with tyrosine nitration levels (P=0.032) and negatively with total antioxidant capacity (P=0.002; Table II in the online-only Data Supplement). Association studies revealed that carotid intima media thickness (CIMT) was strongly associated with anti-CCP levels (P<0.01; Figure I in the online-only Data Supplement). Additionally, pathological CIMT was associated with increased levels of inflammatory molecules (CRP, MCP-1, and MIP1α) and oxidative stress markers, such as decreased antioxidant capacity ( Figure I in the online-only Data Supplement). These results indicate a direct relationship between oxidative stress and inflammation in the development of atherosclerosis in RA.
No significant correlation was observed between the traditional risk factors (obesity, diabetes mellitus, and hypertension) and the inflammatory parameters and oxidative markers analyzed in RA patients.
Differential Expression of Inflammatory Molecules in Leukocytes in RA
Reverse transcriptase-polymerase chain reaction analysis showed that monocytes were the main contributors to the high levels of IL-1β, TNFα, MCP-1, tissue factor (TF), and IL-8 observed in RA patients (Figure 2A , 2B, and 2D-2F), whereas both monocytes and lymphocytes were the source of IL-6 ( Figure 2C ).
As expected, only lymphocytes expressed IL-17 and IL-2, mRNA, with a great elevation in RA patients versus healthy donors ( Figure 2G and 2H). Even though IL-23 expression was detected in all leukocyte types, only RA lymphocytes showed a significant increase of this cytokine compared with controls ( Figure 2L ).
Lymphocytes from healthy donors showed higher IL-10 mRNA expression compared with RA lymphocytes, whereas RA monocytes had increased IL-10 mRNA expression, although this increment does not seem to account for the high levels of IL-10 found in plasma ( Figure 2J ), suggesting that might be a mechanism of compensation. Values are means±SEM. Anti-CCPs indicates anticyclic citrullinated proteins; CIMT, carotide intime media thickness; CRP, C reactive protein; DAS, disease activity score; ESR, erythrocyte sedimentation rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NSAIDS, non-steroideal anti-inflammatory drugs; RA, rheumatoid arthritis; RF, rheumatoid factor; and TNF, tumor necrosis factor. *Significant differences vs controls (P<0.01).
Despite macrophage migration inflammatory factor alpha was found largely elevated in plasma from RA patients ( Table  I in the online-only Data Supplement), mRNA expression of macrophage migration inflammatory factor alpha was significantly lower in RA monocytes and lymphocytes versus controls ( Figure 2I ).
Neutrophils from RA patients displayed high levels of MCP-1 alongside monocytes ( Figure 2D ). These cells may be also responsible for the elevation of MIP-1α in plasma of RA patients ( Figure 2K ).
Leukocyte Activation in RA Patients
CD11a, CD11b, CD62L, and CD66b are well-known leukocyte activation markers needed for the adherence to the endothelium and atherogenesis process. In our cohort of RA patients, we found a significantly higher expression of CD11b on monocytes and neutrophils (P<0.01). RA neutrophils further showed an increase in the cell surface expression of CD11a and CD66b (P<0.05; Table III in the online-only Data Supplement).
Anti-CCPs Antibodies Induce a ProOxidative Status in Healthy Leukocytes
To characterize the anti-CCP antibodies, we investigated the IgG subclasses of anti-CCPs isolated from serum of 15 RA patients, having high titers of anti-CCPs and no RF. In accordance with a recent study, 20 IgG1 followed by IgG4 were the predominant subclasses among anti-CCP antibodies ( Figure II in the online-only Data Supplement).
After 1 hour of treatment with 5 U/mL of anti-CCPs, we found a significant increase in the levels of peroxides in healthy monocytes and neutrophils when comparing to treatment with synthetic IgG ( Figure 3A) . Additionally, the percentage of cells with depolarized mitochondria significantly rose in all leukocyte subsets after anti-CCP treatment ( Figure 3B ). In contrast, addition of anti-CCPs caused a drop in GSH (glutathione) levels ( Figure 3C ).
Anti-CCP Antibodies Promote a Distinct Proinflammatory Profile in Healthy Leukocytes
Anti-CCPs significantly increased the mRNA expression of IL1β, TNFα, MCP-1, TF, and IL-8 in healthy monocytes, in agreement with the results found in vivo in RA patients ( Figure 4A , 4B, and 4D-4F). Neutrophils also responded to the treatment with anti-CCPs, and an augmentation of IL1β, MCP-1, and IL-8 was further observed on these cells ( Figure 4A , 4D, and 4F).
In accordance with the vivo studies, anti-CCPs elevated the mRNA expression levels of IL-6 in lymphocytes and monocytes ( Figure 4C ). A significant increase was also noticed in IL-2 and IL-23 mRNA levels in lymphocytes after anti-CCPs addition ( Figure 4H and 4L) . Alongside lymphocytes, neutrophils were the cell type that expressed higher levels of IL-23 in response to anti-CCP treatment ( Figure 4L ). In agreement with the in vivo studies, in vitro anti-CCP treatment elevated the expression of MIP-1α mRNA in healthy neutrophils, confirming that anti-CCP antibodies are responsible for the augmented MIP-1α expression in neutrophils and its elevation in plasma from RA patients ( Figure 4K ). In contrast to that observed in RA patients, no changes in IL-17 expression were observed between IgG and anti-CCP treatments in lymphocytes (data no shown). Although no differences were seen in the expression of vascular endothelial growth factor and its receptor, vascular endothelial growth factor-R1, comparing leukocytes from controls and RA patients (data not shown), we detected a significant increase of these proteins in monocytes and neutrophils after anti-CCP treatment ( Figure 4I and 4J) . Finally, the altered expression of IL-10 in RA monocytes and lymphocytes was fully recapitulated in these cell types after treatment with anti-CCPs ( Figure 4G ). To further validate the specificity of the anti-CCP antibodies, healthy lymphocytes, monocytes, and neutrophils were treated with total IgGs from 3 RA patients depleted or nondepleted in anti-CCPs, IgGs from pooled sera of 4 healthy donors, IgGs from pooled sera of 4 patients with ankylosing spondylitis (nonautoimmune inflammatory disease), and a commercial monoclonal anti-CCP (anti-citrullinated fibrinogen). The depletion of anti-CCP activity in IgGs-RA patients was 40% to 70%, depending on the initial activity observed in each RA sample, probably because of the excess of column binding capacity ( Figure III in the online-only Data Supplement).
The results showed that the increased expression of genes induced by isolated anti-CCPs (through ELISA method) was recapitulated when treating healthy leukocytes with total IgGs from RA patients. Thus, mRNA expression of MIP-1α, IL-23, and MCP-1 was increased in neutrophils, IL-2 and IL-23 was elevated in lymphocytes, and IL-1b, MCP-1, IL-6, TF, and vascular endothelial growth factor was upregulated in monocytes after treatment with 500 μg RA IgGs ( Figure 5 ). To demonstrate the specificity of anti-CCPs, leukocytes were treated with RA IgGs depleted in anti-CCPs. A significant reduction of the mRNA expression of these genes was observed ( Figure 5) .
Moreover, the monoclonal anti-CCP promoted a significant elevation of the expression of all the genes evaluated. On the contrary, no effects in the expression of these genes were noticed after treatment with IgGs from ankylosing spondylitis patients, indicating the role of autoimmune system in the pathology of RA.
Anti-CCP Antibodies Increase the Expression of Leukocyte Activation Markers
After 6 hours treatment with anti-CCPs, a significant elevation of CD11b and CD66b was observed in neutrophils (P=0.019 and P=0.045, respectively) and an increase of CD11a was detected in monocytes (P=0.010; Table IV in the online-only Data Supplement). These results indicated that anti-CCPs are directly responsible for leukocyte activation and might, therefore, be involved in the vascular complications and the development of atherosclerosis associated to RA.
Anti-CCP Antibodies Induce Apoptosis and Impair Macrophage Function
Anti-CCP treatment during 24 hours induced apoptosis in THP-1 (human monocyte-like cell line)-derived 
Discussion
Anti-CCPs are highly specific predictive and diagnostic markers of RA, [21] [22] [23] and they have been found to be pathogenic in experimental murine models of arthritis. 24, 25 In humans, there is a close relationship between anti-CCP levels and inflammation, oxidative stress, and atherosclerosis associated to RA. 26 Nevertheless, the direct effects of these auto-antibodies in the function of the human leukocytes and macrophages have not been studied yet. Here we show for the first time that anti-CCP antibodies act as direct inductors of the pro-oxidative status, inflammatory and atherogenic profile of lymphocytes, monocytes, and neutrophils in the CVD associated to RA. In addition, effects on macrophage activation and alteration of its apoptotic program are also reported.
Oxidative stress has been described in RA, and growing evidence suggests it could be used for earlier diagnosis of RA. 27 Here, we confirm the increased oxidative stress and impaired antioxidant capacity in RA both at plasma and cellular levels. In our cohort, RA plasma had high levels of oxidative stress markers and diminished levels of antioxidant capacity. These results are in agreement with recent studies showing a pro-oxidative status and impairment of antioxidant capacity in RA, measured as altered levels of malondialdehyde, GSH, GSH Px (GSH peroxidase), GSH reductase, superoxide dismutase, catalase, glucose-6-phosphate, vitamin E, and total NO. 27, 28 Although studies at plasma levels are well defined, the investigations at cellular level are more limited. In our study, neutrophils and monocytes from RA patients showed mitochondrial depolarization, increased reactive oxygen species and peroxynitrite levels, and lower levels of GSH. These results agree with a recent study showing enhanced production of superoxide and peroxynitrites in monocytes and neutrophils of RA patients. 29 Interestingly, in our cohort of patients, no changes in oxidative stress were seen in lymphocytes. Yet, other authors have described an alteration in mitochondria polarization and cell surface-thiols in lymphocytes from RA patients. 30, 31 This could be because of the different disease score or the percentage of patients with high anti-CCP titers. Our data were further supported by in vitro studies, demonstrating the direct effect of anti-CCPs in the induction of an oxidative status in monocytes and neutrophils.
The association between oxidative stress and anti-CCPs was also validated by a recent study showing that a deletion polymorphism in glutathione S-transferase Mu-1 (antioxidant enzyme) was associated with anti-CCP positivity, 32 suggesting that oxidative stress might be involved in the development of RA-specific autoimmunity in genetically susceptible subjects. Moreover, a recent study showed an increased synovial oxidant activity in anti-CCP-positive RA patients compared with RA patients negative for anti-CCPs. 33 It is well established that cytokine networks play a critical role in the pathogenesis of RA. There is an elevation of proinflammatory cytokines in RA plasma and synovium fluid (reviewed in 34 ). Accordingly, our cohort of RA patients displayed elevated plasma levels of proinflammatory cytokines, which, in addition, strongly correlated with elevated levels of anti-CCPs in plasma, suggesting a role for these autoantibodies in the inflammatory profile associated with RA. In support for this notion, there is evidence of a different cytokine profile associated with anti-CCP or RF antibodies. 35 Moreover, it has been shown that anti-CCP-positive patients had significant higher levels of IL1β, IL-10, and IL-17 in their synovial fluid than anti-CCP-negative patients, 36 which is in line with our data in plasma from RA patients.
Searching the source of these proinflammatory molecules, we observed a different profile for each cell type: lymphocytes, monocytes, and neutrophils. RA lymphocytes particularly expressed elevated levels of IL17, IL2, IL6, and IL23 and decreased levels of IL-10. Interestingly, in vitro treatment with anti-CCPs fairly recapitulated the proinflammatory profile seen in RA lymphocytes, increasing the expression of IL2, IL6, and IL23 and lowering the expression of IL-10.
The role of these cytokines has extensively been described in the development of different T cell subsets in RA, such as Th1, Th17, and Treg cells. 34 Our study suggests that anti-CCPs might promote the differentiation of Th1 and the impairment of Treg cells, main characteristics of the physiopathology of RA. IL-17 is a newly identified cytokine associated with the pathogenesis of RA and describing the specific cell subtype: Th17. Number of Th17 cells is increased in peripheral blood of RA patients, and IL-17, which is greatly released in plasma and synovial fluid, has relevant roles mediating inflammation, microvascular function, and atherosclerosis. [37] [38] [39] On the contrary, although IL-17 levels strongly correlated with anti-CCP levels, in vitro treatment of normal lymphocytes with antiCCPs did not induce its expression. In this regard, it has been demonstrated that monocytes and fibroblasts from inflamed joints are able to induce the development of Th17 cells, 40, 41 suggesting that interactions with other activated cells might be further required to induce the expression of IL17.
Despite RA is recognized as Th-driven disease, monocytes/ macrophages are important effectors in its pathology, being central players in inflammation and atherosclerosis. In our cohort of RA patients, a significant rise in IL1β, TNFα, IL6, MCP1, IL-8, and TF mRNA was observed in peripheral monocytes. Of note, in vitro anti-CCP treatment of healthy monocytes and THP-1-derived macrophages fully recapitulated this procoagulant and inflammatory profile. Additionally, this aspect was further supported by the direct relationship found in vivo between anti-CCP titers and levels of inflammatory molecules. Macrophages plasticity plays a central role during the development of RA. 42 Anti-CCP treatment promoted the expression of inflammatory cytokines typically associated to the classical inflammatory macrophage M1 state. This data points to anti-CCP antibodies as inductors of the M1 polarization in RA. Interestingly, increasing anti-CCP doses promoted apoptosis in macrophages. Accumulating evidence indicates that impaired apoptosis represents a mechanism underlying the pathogenesis of RA. Although apoptotic cells are rarely found in RA tissues in vivo, diverse RA cells have often been observed to express high levels of Fas cell surface death receptor and are highly susceptible to apoptosis in vitro, likely reflecting multiple antiapoptotic processes or alteration in the normal apoptosis program in RA. 43 In that way, elevated levels of Fas cell surface death receptor mRNA and other pro/ antiapoptotic molecules (p53, B-cell lymphoma 2-interacting killer, and Bcl-2) was shown after treatment with anti-CCPs, suggesting that the alteration in the apoptosis process in RA could be because of the action of anti-CCP antibodies.
Neutrophils play a relevant role in RA, being the predominant cells in synovial fluid. MIP-1α is highly expressed by RA neutrophils from synovial fluid, contributing to the recruitment of mononuclear cells from the bloodstream into synovium. 44 According to previous evidence, we found high MIP-1α levels in plasma from RA patients. 45 Adding new data about the source of this molecule in plasma, we show that RA neutrophils were the cells expressing highest MIP-1α mRNA levels compared with healthy donors, indicating that they are the main responsible for elevated blood MIP-1α levels in RA. Moreover, a strong correlation was observed between MIP-1α and anti-CCP levels, indicating that anti-CCPs are directly involved in the production of this chemokine. We further confirm this hypothesis showing that anti-CCPs significantly increased levels of MIP-1α in healthy neutrophils, whereas no changes were seen in monocytes and lymphocytes. Neutrophils have been shown to produce a large variety of proinflammatory cytokines and proresolving mediators. In addition, the direct interaction of neutrophils with macrophages, dendritic cells, natural killer cells, and lymphocytes modulates the immune response. 46 In that way, we could demonstrate that treatment of neutrophils with anti-CCPs induced in the expression of higher number of inflammatory molecules than those observed in vivo in RA neutrophils. These data further suggest the relevant role of anti-CCPs as inductors of an inflammatory profile in neutrophils.
The prevalence of CVD in RA patients is well documented, and anti-CCP antibodies have been linked to an adverse cardiovascular profile. 26 In agreement with the existing body of literature, we found altered diverse parameters strongly associated with the development of atherosclerosis in RA patients. Thus, an increased presence of activation markers in neutrophils and monocytes and elevated expression of TF in monocytes were seen in RA patients. Additionally, 21.3% RA patients had pathological CIMT, and there was a strong association between pathological CIMT and DAS28, CRP levels, MCP-1 plasma, MIP-1α levels and low TAC and anti-CCP levels. These results are in agreement with a study, indicating that anti-CCP-positive RA patients had higher CIMT than patients without evidence of these antibodies. 47 Moreover, it has been shown that citrullinated proteins are prevalent within atherosclerotic plaques, and certain anti-CCP antibodies are correlated with the CIMT 48 and associated with the atherosclerotic burden. 49 In this sense, treatment of healthy leukocytes with anti-CCPs resulted in an elevation of cell activation markers in monocytes and neutrophils, an increase of TF expression, inflammation, and oxidative stress, indicating the participation of these autoantibodies in the development of atherosclerosis and CVD.
Although anti-CCP-positive and anti-CCP-negative patients display similar clinical features, they have a different disease course, being more severe in anti-CCP-positive RA patients. Here we demonstrate that anti-CCP antibodies may directly increase the risk of CVD in RA. This was confirmed through both the associations among anti-CCP levels and parameters related to inflammation, oxidative stress, and atherosclerosis in vivo and the in vitro treatment of healthy leukocytes with anti-CCPs. Thus, anti-CCPs activate leukocytes and change their phenotype to an atherogenic profile through the (a) alteration of the oxidative status in monocytes and neutrophils, (b) promotion of the Th-1 differentiation and the impairment of Treg cells, (c) modulation of the MIP-1α expression in neutrophils, increasing the migratory properties of mononuclear cells, (d) elevation of the inflammatory and procoagulant monocyte activity, and (e) the polarization of macrophages to a classical inflammatory M1 state and alteration of the apoptosis program in macrophages.
Targeting these autoantibodies would be an excellent strategy to prevent the development of CVD associated with RA.
